Prevision Medicine raises $5.4M seed for functional cancer testing

Prevision Medicine, a Zurich-based functional precision oncology company, has raised $5.4M in seed funding led by Swiss early-stage firm ACE Ventures, with GoHub Ventures, SICTIC and oncology-focused angel investors participating, to fund regulatory clearances, reimbursement coverage and expansion across Europe.

The round was announced on 24 September 2026. It is a small cheque by this week’s standards – and that is exactly why it is worth reading closely. Below, I lay out the round, the platform behind it, and what a reimbursement-first seed says about how Swiss health capital works.

A seed round aimed at insurers, not just labs

ACE Ventures, the Swiss early-stage investor, leads the $5.4M seed (company announcement, 24 Sep 2026). GoHub Ventures and SICTIC, the Swiss ICT Investor Club whose angels have become a fixture of the country’s deep tech seed rounds, join the syndicate alongside angel investors focused on oncology and precision medicine.

The use of funds is unusually concrete for a seed stage company: regulatory clearances, reimbursement coverage, and operational expansion across Europe. “With this funding and support from key partners, including molecular tumor boards and insurers, we are positioned to improve patient outcomes and deliver cost-effective cancer care,” says CEO Philip Zimmermann in the announcement. Note the word insurers. Most seed decks promise product velocity; this one promises a billing code.

Testing living tumour cells against 100+ treatments

Founded in 2024, Prevision Medicine runs its laboratory at ETH Hönggerberg in Zurich, with a second base at the Biopôle campus near Lausanne. Its PrevisionOne platform takes a patient’s fresh biopsy sample, exposes the living cancer cells to a library of more than 100 drugs and drug combinations, and uses automated microscopy with AI-driven single-cell analysis to rank which treatments kill the cancer cells more selectively than the healthy ones – with a clinical report back in three days, per the company. It covers both haematological malignancies and solid tumours.

The approach is called functional precision medicine, and the difference from the sequencing-first standard matters. Genomics tells a physician what a tumour is; functional testing shows what it actually responds to. The company says the underlying science has been validated with more than 20 European hospitals across 2,000 patient samples, with peer-reviewed publications in Nature Medicine, Nature Communications and Cancer Discovery. “Prevision Medicine has made a clinically validated technique economically viable,” says Pablo Perea, partner at GoHub Ventures, in the announcement.

The fastest-growing corner of a $115.8bn market

Precision oncology is not a niche. The global market stood at $115.8bn in 2024 and is projected to reach $202.0bn by 2030, an 8.1% CAGR for 2025-2030, with diagnostics the fastest-growing segment at 8.6% (Grand View Research, Jan 2025). The interesting part for a company like Prevision is that the diagnostics layer grows faster than the therapeutics it serves: every new targeted drug makes the question “which one for this patient?” more valuable.

For scale within our own tracking: Kasvu Therapeutics raised a €30M Series A in Helsinki this same week, and Paris-based HighLife pulled in $90M+ for its mitral valve. Against those, $5.4M looks modest. It is also the round that costs the least and de-risks the most: reimbursement decisions, not molecules, are the gate this company has to pass.

What Swiss health seeds keep getting right

So what is actually happening here? This is the third European health round we have covered this week, across three geographies and three stages – a French medtech growth round, a Finnish biotech Series A, now a Swiss diagnostics seed. The capital is not concentrated in one hub; it is distributed across the continent’s university systems, and that is the pattern the headlines keep missing.

The Swiss version of that system is particularly legible in this round: an ETH campus laboratory, a syndicate anchored by SICTIC’s angel network, and a business plan written around Europe’s payer landscape rather than against it. In the US, precision oncology grew up as a venture-scale sequencing race. Europe’s fragmented insurers and national health systems are usually framed as the roadblock – and the fact remains they slow everything down. The silver lining is that a company forced to win reimbursement early builds the one asset that compounds: evidence that convinces the people who pay. What we are seeing, from Zurich to Helsinki, is health startups treating Europe’s payers as the product spec.

Worth watching: whether Prevision lands its first reimbursement coverage in Switzerland before expanding, and which university hospital networks sign on next. The full round record is in our fundraising database, updated daily. European health capital is quietly building its own playbook – let’s keep tracking it.